ammonia N-13
Commercial- Indications
- Coronary artery disease
Company intelligence / Profile preview
Ionetix has established a nationwide network of compact cyclotrons to provide on-demand production of N13 Ammonia for advanced cardiac PET imaging. The company is also scaling up commercial-stage production of key therapeutic alpha-emitting isotopes such as Actinium‑225, supporting the development and future commercialization of targeted alpha therapies in oncology. Recent milestones include successful high-purity Ac‑225 production at their dedicated Michigan facility.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Ionetix.